&nbsp;

Sep 2025

Drug

bosutinib

Other Name(s): Bosulif®

Quick Link(s):

Nov 2024

Drug

ceritinib

Other Name(s): Zykadia™

Quick Link(s):

Nov 2024

Drug

idelalisib

Other Name(s): Zydelig™

Quick Link(s):

Feb 2022

Drug

ponatinib

Other Name(s): Iclusig®

Quick Link(s):

Aug 2023

Drug

cobimetinib

Other Name(s): Cotellic™

Quick Link(s):

Nov 2024

Drug

lenvatinib

Other Name(s): Lenvima®

Quick Link(s):

Sep 2023

Drug

palbociclib

Other Name(s): Ibrance™

Quick Link(s):

Oct 2025

Drug

venetoclax

Other Name(s): Venclexta®

Quick Link(s):

Aug 2025

Drug

midostaurin

Other Name(s): Rydapt®

Quick Link(s):

Jun 2025

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

, Collapse Show fewer tags

Drugs Used:

daSATinib

... Show more tags

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

SUNI

Cancer Type:

Gastrointestinal,

Gastrointestinal Stromal Tumours,

Sarcoma,

GIST

Intent: Palliative

Funding:

Exceptional Access Program

SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria